Guardant Health (GH) is higher in Tuesday trading as the market revisits the company’s newly activated Quest Diagnostics pathway for its Shield blood-based colorectal cancer (CRC) screening test. Guardant announced on March 10, 2026 that Shield is now broadly accessible for physician order through Quest’s national ordering and specimen-collection network, positioning the test for wider primary-care adoption and smoother workflow integration.

The Quest rollout is a distribution and commercialization catalyst: physicians who already use Quest can order Shield through existing Quest accounts and electronic health record (EHR) workflows, while patients can access blood draws via Quest’s footprint of about 2,000 patient service centers and about 6,000 in-office phlebotomists. Guardant also said Quest’s national commercial sales team will educate primary care physicians on access to Shield, which can translate into higher awareness and faster scaling of routine screening volumes.

Guardant positions Shield as the first and only blood test with full FDA approval as a primary CRC screening option for average-risk adults age 45 and older. The company highlighted a 93% real-world screening adherence rate in the first 100,000 Shield tests ordered and noted that Shield is covered by Medicare, the Veterans Affairs Community Care Network and TRICARE, and is commercially available across the U.S., supporting the investment case for continued screening expansion.